T2 Biosystems

297 articles about T2 Biosystems

• T2 Biosystems Reports Granting of Inducement Award - June 26, 2020

  6/26/2020

  T2 Biosystems, Inc. a leader in the rapid detection of sepsis-causing pathogens, announced that it issued inducement awards to four new employees.

• T2 Biosystems Regains Compliance with NASDAQ Listing Requirements

  6/17/2020

  T2 Biosystems, Inc. announced that on June 16, 2020 it received written notice from the Nasdaq Listing Qualifications Staff of the NASDAQ Stock Market LLC stating that the Company regained compliance with the applicable Nasdaq minimum bid price continued listing requirement and the matter is now closed.

• T2 Biosystems Announces Changes to Board of DirectorsThree new appointments add significant clinical and commercialization experience and expand board diversity

  6/15/2020

  T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced three new Board of Director appointments.

• T2 Biosystems’ Bacteria Panel Wins “Best New Technology Solution - Diagnostics" Award in MedTech Breakthrough Awards

  5/19/2020

  T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced it won the “Best New Technology Solution - Diagnostics" award for its T2Bacteria® Panel solution in the fourth annual MedTech Breakthrough Awards program.

• T2 Biosystems Announces First Quarter 2020 Financial Results

  5/5/2020

  T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens, announced financial results for the first quarter ended March 31, 2020.

• T2 Biosystems to Report First Quarter 2020 Financial Results on May 5, 2020

  4/21/2020

  T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens, announced that it will report financial results for the first quarter of 2020 after market close on Tuesday, May 5, 2020.

• T2 Biosystems Reports Granting of Inducement Award - April 15, 2020

  4/15/2020

  T2 Biosystems, Inc. a leader in the rapid detection of sepsis-causing pathogens, announced that it issued inducement awards to four new employees.

• T2 Biosystems Announces Worldwide Licensing Agreement of COVID-19, Novel Coronavirus Assay from Hackensack Meridian Health’s Center for Discovery and Innovation

  3/24/2020

  New COVID-19 assay will be adapted to run on T2 Biosystems’ FDA-cleared T2Dx® Instrument

• T2 Biosystems Announces Preliminary First Quarter 2020 Financial ResultsSuspends 2020 Financial Guidance

  3/24/2020

  T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced unaudited, preliminary financial result estimates for the quarter ended March 31, 2020, and suspended full year 2020 financial and operational guidance due to uncertainties from the impact of the novel coronavirus (COVID-19) pandemic.

• T2 Biosystems Receives Multiyear Innovative Technology Contract from Vizient, Inc. Contract recognizes products that bring improvements to the health care industry

  3/19/2020

  T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that it was awarded an Innovative Technology contract from Vizient, Inc., the largest member-driven health care performance improvement company in the country, covering its T2Dx ® Instrument, as well as the T2Bacteria ® and T2Candida ® Panels, that detect sepsis-causing bacterial and fungal pathogens directly from whole blood.

• T2 Biosystems Announces Fourth Quarter and Full Year 2019 Financial Results

  2/24/2020

  LEXINGTON, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced financial results for the fourth quarter and full year ended December 31, 2019. Fourth Quarter and Recent Business and Financial Performance Highlights Achieved fourth quarter total revenue of $3.1 million and product revenue of $1.6 million, representing increases of 71% and 18% respectively, compared to the prior year period

• T2 Biosystems to Participate in the SVB Leerink Global Healthcare Conference

  2/19/2020

  T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the Company plans to participate in the upcoming SVB Leerink Global Healthcare Conference in New York, New York.

• T2 Biosystems to Report Fourth Quarter and Full Year 2019 Financial Results on February 24, 2020

  2/12/2020

  T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financial results for the fourth quarter and full year 2019 after market close on Monday, February 24, 2020.

• T2 Biosystems Announces Participation at Clinical Conferences in FebruaryCompany will highlight need for rapid detection of sepsis-causing pathogens

  2/4/2020

  LEXINGTON, Mass., Feb. 04, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the Company’s participation in two conferences in February: Society of Critical Care Medicine’s (SCCM) 48th Critical Care Congress, and Medlab Middle East 19th Annual Laboratory Management and Medicine Conference. “A recent study in The Lancet estimated that 11 million people died with sepsis in 2017 -- accounting for nearly 20% o

• T2 Biosystems Reports Granting of Inducement Award

  1/17/2020

  T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that it issued an inducement award to John Sperzel, the Company’s recently appointed Chief Executive Officer and President,

• T2 Biosystems Promotes Tony Pare to Chief Commercial Officer

  1/13/2020

  T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, today announced that its Chief Executive Officer (CEO), John Sperzel, has promoted Tony Pare to the newly created position of Chief Commercial Officer (CCO), effective immediately. Mr. Pare previously served as Vice President and General Manager – International at T2 Biosystems.

• T2 Biosystems Appoints Industry Veteran John Sperzel as Chief Executive Officer

  1/9/2020

  T2 Biosystems, Inc., a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced that its Board of Directors has appointed diagnostics industry veteran John Sperzel as President and Chief Executive Officer, effective immediately.

• T2 Biosystems Announces Preliminary Fourth Quarter 2019 Financial ResultsEnters Exclusive Distribution Agreement to Expand Sales in Israel

  1/9/2020

  Fourth quarter total revenue of approximately $3.0 million, an increase of 67% compared to the prior year period.

• T2 Biosystems Reports Granting of Inducement Awards - Dec. 13, 2019

  12/13/2019

  T2 Biosystems, Inc., a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced that on December 4, 2019 it issued inducement awards to two new employees.

• T2 Biosystems to Present at the 13th Annual Canaccord Genuity Medical Technology & Diagnostics Forum

  11/15/2019

  T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company,”“T2,” or “T2 Biosystems”), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that John McDonough, chairman and chief executive officer, and John Sprague, chief financial officer, are scheduled to present at the 13th Annual Canaccord Genuity Medical Technology & Diagnostics Forum